11 July 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc (“Abingdon”) in relation to the manufacture and supply of AbC-19™ Rapid tests, a COVID-19 lateral flow antibody test.
The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care (“DHSC”) on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon.
|Omega Diagnostics Group PLC||www.omegadx.com|
|Jag Grewal Chief Executive Officer||via Walbrook PR|
|Chris Lea, Chief Financial Officer|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)|
|Alice Lane/ Harriet Ward (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Applegarth||Mob: 07584 391 303|
|Sam Allen||Mob: 07502 558 258|
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com